


Health Alert Network Message 21-49: Recommendations on Continuing to Vaccinate Adolescents Against COVID-19

Origination Date: *June 25, 2021*

Revision Dates (List All Revision Dates):

ACIP Recommends Continuing to Vaccinate Adolescents Against COVID-19, Stating That the Benefits of Vaccination Far Outweigh the Risks. Encourage Continued Surveillance for Myocarditis/Pericarditis. Recommendations for Vaccination in Persons with a History of Pericarditis/Myocarditis.

Yesterday (6/23), the American Council on Immunization Practice (ACIP) meeting included a discussion around cases of myocarditis/pericarditis after mRNA COVID-19 vaccination. There were no votes during this meeting. ACIP voting members discussed the risks and benefits of vaccinating adolescents against the risk of myocarditis. Voting members agreed that the benefits continue to outweigh the harms, but this inflammatory condition needs to continue to be monitored with additional race/ethnicity data and additional data on myocarditis risk after dose 1 vs. dose 2 of mRNA vaccines.



Recommendations for Clinicians

• CDC continues to recommend COVID-19 vaccination for everyone 12 years and older given the greater risk of other serious complications related to COVID-19, such as hospitalization, multisystem inflammatory syndrome in children (MIS-C), or death.

Vaccine Considerations in People with a History of Myocarditis or Pericarditis:

Vaccine considerations in people with a history of myocarditis or pericarditis

Scenario	Recommendation
Pericarditis prior to COVID-19 vaccination	Receive any FDA-authorized COVID-19 vaccine
Pericarditis after 1 st dose of an mRNA COVID-19 vaccine but prior to 2 nd dose	Proceed with a 2 nd dose of mRNA COVID-19 vaccine after resolution of symptoms. Discuss with patient, guardian, and clinical team
Myocarditis prior to COVID-19 vaccination	Receive any FDA-authorized COVID-19 vaccine if heart has recovered
Myocarditis after 1 st dose of an mRNA COVID-19 vaccine but prior to 2 nd dose	Defer 2 nd dose of mRNA COVID-19 vaccine until more information is known However, if heart has recovered, could consider proceeding with 2 nd dose under certain circumstances. Discuss with patient, guardian, and clinical team

Report all cases of myocarditis and pericarditis post COVID-19 vaccination to VAERS , and to Louisiana Department of Health, Infectious Disease Epidemiology Clinician Hotline: 800-256-2748.